Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma

#2259

Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.

Aim(s): To analyze treatment outcomes of PNEC patients.

Materials and methods: Retrospective analysis of all patients PNECs including mixed differentiation with adenocarcinoma component at two oncological centers between 12/2000 and 11/2017.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Apostolidis L, Nientiedt C, Winkler E, Stenzinger A, Duensing S,

Keywords: neuroendocrine carcinoma, prostate, chemotherapy, immunotherapy,